Accès libre

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Amrallah A. Mohammed

Amrallah A. Mohammed

Medical Oncology Department, Faculty of Medicine, Zagazig UniversityEgypt
Recherchez cet auteur sur
Sciendo|Google Scholar
Mohammed, Amrallah A.
, 
Hanna M. Ibrahim

Hanna M. Ibrahim

Department of Pathology, Faculty of Medicine, Zagazig University
Recherchez cet auteur sur
Sciendo|Google Scholar
Ibrahim, Hanna M.
, 
Hanna A. Atwa

Hanna A. Atwa

Department of Pathology, Faculty of Medicine, Zagazig University
Recherchez cet auteur sur
Sciendo|Google Scholar
Atwa, Hanna A.
, 
Ayman Elshentenawy

Ayman Elshentenawy

Kasr EL Einy center of clinical oncology and nuclear (NEMROCK), Cairo universityEgypt
Recherchez cet auteur sur
Sciendo|Google Scholar
Elshentenawy, Ayman
 et 
Amira Elwan

Amira Elwan

Clinical oncology Department, Faculty of Medicine, Zagazig UniversityEgypt
Recherchez cet auteur sur
Sciendo|Google Scholar
Elwan, Amira
  
05 avr. 2020
Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Télécharger la couverture
Catégorie d'article: Research Article
Publié en ligne: 05 avr. 2020
Pages: 15 - 25
Reçu: 03 août 2018
Accepté: 21 juil. 2019
DOI: https://doi.org/10.2478/fco-2019-0005
Mots clés
© 2019 Amrallah A. Mohammed et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Figure 1

Staining of cyclin D1 and DJ-1 in benign prostatic hyperplasia and prostatic adenocarcinoma: A)Benign prostatic hyperplasia showing negative cyclin D1 staining (ABC × 400)B)High grade prostatic adenocarcinoma showing strong Cyclin D1 staining (ABC × 200)C)Benign prostatic hyperplasia showing faint DJ1 intensity (ABC × 100)D)High grade Prostatic adenocarcinoma with strong DJ1 intensity (ABC × 400)
Staining of cyclin D1 and DJ-1 in benign prostatic hyperplasia and prostatic adenocarcinoma: A)Benign prostatic hyperplasia showing negative cyclin D1 staining (ABC × 400)B)High grade prostatic adenocarcinoma showing strong Cyclin D1 staining (ABC × 200)C)Benign prostatic hyperplasia showing faint DJ1 intensity (ABC × 100)D)High grade Prostatic adenocarcinoma with strong DJ1 intensity (ABC × 400)

Figure 2

Bar chart shows percent of relapse among different studied subpopulation of prostatic carcinoma patients.
Bar chart shows percent of relapse among different studied subpopulation of prostatic carcinoma patients.

Figure 3

Bar chart shows percent of hormone refractory relapse among different studied subpopulation of prostatic carcinoma patients
Bar chart shows percent of hormone refractory relapse among different studied subpopulation of prostatic carcinoma patients

Figure 4

ROC curve for sensitivity and specificity of cyclin D1 in prediction of prostatic carcinoma
ROC curve for sensitivity and specificity of cyclin D1 in prediction of prostatic carcinoma

Figure 5

ROC curve for sensitivity and specificity of DJ-1 in prediction of prostatic carcinoma
ROC curve for sensitivity and specificity of DJ-1 in prediction of prostatic carcinoma

Comparison between PC and BPH as regard cyclin D1 and DJ-1 (staining and overexpression)

Prostatic Carcinoma (N=40)Prostatic Hyperplasia (N=40)p-value‡
No.(%)No.(%)
Cyclin D1 extent
Negative2(5%)39(97.5%)< 0.001
Positive38(95%)1(2.5%)
DJ1 extent
Negative6(15%)39(97.5%)< 0.001
Positive34(85%)1(2.5%)
Cyclin D1 extent /DJ1 extent
Negative/Negative2(5%)38(95%)< 0.001
Negative/Positive0(0%)1(2.5%)
Positive/Negative4(10%)1(2.5%)
Positive/Positive34(85%)0(0%)
Cyclin D1 intensity
02(5%)39(97.5%)< 0.001
15(12.5%)1(2.5%)
216(40%)0(0%)
317(42.5%)0(0%)
DJ1 intensity
06(15%)39(97.5%)< 0.001
14(10%)0(0%)
214(35%)1(2.5%)
316(40%)0(0%)
Cyclin D1 intensity/DJ1 intensity
0/02(5%)38(95%)< 0.001
0/10(0%)0(0%)
0/20(0%)1(2.5%)
1/01(2.5%)1(2.5%)
1/14(10%)0(0%)
1/20(0%)0(0%)
2/03(7.5%)0(0%)
2/10(0%)0(0%)
2/210(25%)0(0%)
2/33(7.5%)0(0%)
3/24(10%)0(0%)
3/313(32.5%)0(0%)
Cyclin D1 overexpression
Negative23(57.5%)
Positive17(42.5%)
DJ-1 overexpression
Negative21(52.5%)
Positive19(47.5%)

Clinicopathological features and outcome of 40 patients with prostatic carcinoma_

CharacteristicsProstatic Carcinoma (N=40)CharacteristicsProstatic Carcinoma (N=40)
No.%No.%
Gleason scoreRelapse
< 7717.5%Absent1640%
= 71127.5%Present2460%
➢72255%
TDistant metastasis
T1512.5%Absent1640%
T21435%Present2460%
T32152.5%
StageHormone Refractory Relapse(N=24)
Stage I37.5%Absent729.2%
Stage IIa615%Present1770.8%
Stage IIb1025%
Stage III2125%

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and relapse in 40 PC patients

Prostatic Carcinoma (N=40)Relapsep-value
Absent (N=16)Present (N=24)
No.(%)No.(%)No.(%)
Gleason score
< 77(17.5%)7(100%)0(0%)< 0.001§
= 711(27.5%)9(81.8%)2(18.2%)
➢722(55%)0(0%)22(100%)
T
T15(12.5%)5(100%)0(0%)< 0.001§
T214(35%)11(78.6%)3(21.4%)
T321(52.5%)0(0%)21(100%)
Stage
Stage I3(7.5%)3(100%)0(0%)< 0.001§
Stage IIa6(15%)6(100%)0(0%)
Stage IIb10(25%)7(70%)3(30%)
Stage III21(25%)0(0%)21(100%)
Cyclin D1 extent
Negative2(5%)2(100%)0(0%)0.154‡
Positive38(95%)14(36.8%)24(63.2%)
DJ1 extent
Negative6(15%)6(100%)0(0%)0.002‡
Positive34(85%)10(29.4%)24(70.6%)
Cyclin D1 extent /DJ1 extent
−ve/−ve2(5%)2(100%)0(0%)0.003§
+ve/−ve4(10%)4(100%)0(0%)
+ve/+ve34(85%)10(29.4%)24(70.6%)
Cyclin D1 intensity
02(5%)2(100%)0(0%)0.002§
15(12.5%)5(100%)0(0%)
216(40%)5(31.3%)11(68.8%)
317(42.5%)4(23.5%)13(76.5%)
DJ1 intensity
06(15%)6(100%)0(0%)< 0.001§
14(10%)4(100%)0(0%)
214(35%)6(42.9%)8(57.1%)
316(40%)0(0%)16(100%)
Cyclin D1 intensity/DJ1 intensity
0/02(5%)2(100%)0(0%)< 0.001§
1/01(2.5%)1(100%)0(0%)
1/14(10%)4(100%)0(0%)
2/03(7.5%)3(100%)0(0%)
2/210(25%)2(20%)8(80%)
2/33(7.5%)0(0%)3(100%)
3/24(10%)4(100%)0(0%)
3/313(32.5%)0(0%)13(100%)
Cyclin D1 overexpression
Negative23(57.5%)16(69.6%)7(30.4%)< 0.001‡
Positive17(42.5%)0(0%)17(100%)
DJ1 overexpression
Negative21(52.5%)16(76.2%)5(23.8%)< 0.001‡
Positive19(47.5%)0(0%)19(100%)

Relation between cyclin D1 and DJ-1 (staining and overexpression), clinicopathological parameters and hormone response in 40 PC patients

Prostatic Carcinoma (N=24)Hormone Refractoryp-value
Absent (N=7)Present (N=17)
No.(%)No.(%)No.(%)
Gleason score
= 72(8.3%)0(0%)2(100%)1.000‡
➢722(91.7%)7(31.8%)15(68.2%)
T
T23(12.5%)1(33.3%)2(66.7%)1.000‡
T321(87.5%)6(28.6%)15(71.4%)
Stage
Stage IIb3(12.5%)1(33.3%)2(66.7%)1.000‡
Stage III21(87.5%)6(28.6%)15(71.4%)
Cyclin D1 extent
Positive24(100%)7(29.2%)17(70.8%)---
DJ1 extent
Positive24(100%)7(29.2%)17(70.8%)---
Cyclin D1 extent /DJ1 extent
+ve/+ve24(100%)7(29.2%)17(70.8%)---
Cyclin D1 intensity
211(45.8%)0(0%)11(100%)0.006‡
313(54.2%)7(53.8%)6(46.2%)
DJ1 intensity
28(33.3%)0(0%)8(100%)0.054‡
316(66.7%)7(43.8%)9(56.3%)
Cyclin D1 intensity/DJ1 intensity
2/28(33.3%)0(0%)8(100%)0.006§
2/33(12.5%)0(0%)3(100%)
3/313(54.2%)7(53.8%)6(46.2%)
Cyclin D1 overexpression
Negative7(29.2%)7(100%)0(0%)<0.001‡
Positive17(70.8%)0(0%)17(100%)
DJ1 overexpression
Negative5(20.8%)5(100%)0(0%)<0.001‡
Positive19(79.2%)2(10.5%)17(89.5%)
Langue:
Anglais
Périodicité:
2 fois par an
Sujets de la revue:
Médecine, Médecine clinique, Médecine interne, Hématologie, oncologie
RSS Feed de la revue